BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31842910)

  • 1. Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.
    Sheng L; Cui X; Cheng L; Chen Y; Du X
    Radiat Oncol; 2019 Dec; 14(1):229. PubMed ID: 31842910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
    Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S
    Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
    Dang J; Li G; Zang S; Zhang S; Yao L
    Radiat Oncol; 2014 Jul; 9():172. PubMed ID: 25074618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
    Katsui K; Ogata T; Watanabe K; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    BMC Cancer; 2019 Nov; 19(1):1144. PubMed ID: 31771538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
    Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
    Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer.
    Guilbault C; Garant A; Faria S; Owen S; Ofiara L; Duclos M; Hirsh V; Kopek N
    Clin Lung Cancer; 2017 Sep; 18(5):565-571. PubMed ID: 28344046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Low dose volume histogram analysis of the lungs in prediction of acute radiation pneumonitis in patients with esophageal cancer treated with three-dimensional conformal radiotherapy].
    Shen WB; Zhu SC; Gao HM; Li YM; Liu ZK; Li J; Su JW; Wan J
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):45-9. PubMed ID: 23648300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
    Oh IJ; Kim KS; Kim YC; Ban HJ; Kwon YS; Kim YI; Lim SC; Chung WK; Nam TK; Song JY; Yoon MS; Ahn SJ
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1247-54. PubMed ID: 24091849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.
    Jang JY; Kim SS; Song SY; Kim YJ; Kim SW; Choi EK
    Radiat Oncol; 2021 Dec; 16(1):231. PubMed ID: 34863244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
    Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
    Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy.
    Jia W; Gao Q; Wang M; Li J; Jing W; Yu J; Zhu H
    Radiat Oncol; 2021 Feb; 16(1):41. PubMed ID: 33622352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion of functional information from perfusion SPECT improves predictive value of dose-volume parameters in lung toxicity outcome after radiotherapy for non-small cell lung cancer: A prospective study.
    Farr KP; Kallehauge JF; Møller DS; Khalil AA; Kramer S; Bluhme H; Morsing A; Grau C
    Radiother Oncol; 2015 Oct; 117(1):9-16. PubMed ID: 26303012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.
    Yu JH; Wang CL; Liu Y; Wang JM; Lv CX; Liu J; Zhang Q; Fu XL; Cai XW
    Cancer Radiother; 2021 Jun; 25(4):323-329. PubMed ID: 33446419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipsilateral lung dose as a correlative measure for radiation pneumonitis in patients treated with definitive concurrent radiochemotherapy.
    Kirakli EK; Erdem S; Susam S; Erim E
    J Cancer Res Ther; 2023; 19(5):1153-1159. PubMed ID: 37787278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy.
    Piotrowski T; Matecka-Nowak M; Milecki P
    Neoplasma; 2005; 52(1):56-62. PubMed ID: 15739028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
    Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y
    Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer.
    Kim TH; Cho KH; Pyo HR; Lee JS; Zo JI; Lee DH; Lee JM; Kim HY; Hwangbo B; Park SY; Kim JY; Shin KH; Kim DY
    Radiology; 2005 Apr; 235(1):208-15. PubMed ID: 15703313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-Volume Parameters Predict Radiation Pneumonitis after Surgery with Induction Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer.
    Ogata T; Katsui K; Yoshio K; Ihara H; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Acta Med Okayama; 2018 Oct; 72(5):507-513. PubMed ID: 30369608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the radiation pneumonia development risk in lung cancer cases.
    Yilmaz S; Adas YG; Hicsonmez A; Andrieu MN; Akyurek S; Gokce SC
    Asian Pac J Cancer Prev; 2014; 15(17):7371-5. PubMed ID: 25227844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.